Related Experiment Video
Updated: Oct 12, 2025
03:06
Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
531
Polidocanol Sclerotherapy in Pyogenic Granulomas
Ananta Khurana1, Sinu Rose Mathachan
1Both authors are affiliated with the Department of Dermatology, Dr. Ram Manohar Lohia Hospital and ABVIMS, New Delhi, India.
Summary
Polidocanol injections effectively treat pyogenic granulomas (PGs) with a 100% clearance rate. This safe and cost-effective sclerotherapy shows no recurrence, making it a promising treatment option.
Area of Science:
- Dermatology
- Dermatologic Surgery
Background:
- Polidocanol is a sclerosing agent known for its safety, anesthetic properties, and low skin toxicity.
- Pyogenic granulomas (PGs) are common vascular lesions that can be challenging to treat.
Purpose of the Study:
- To assess the efficacy, safety, and recurrence rates of polidocanol sclerotherapy for treating pyogenic granulomas.
- To establish polidocanol as a viable treatment for PGs.
Main Methods:
- Thirty-nine patients with PGs received polidocanol 1% injections, with up to three weekly sessions.
- Higher concentration (3%) polidocanol was used for non-responders.
- Patients were followed for 3, 6, and 12 months to assess recurrence.
Main Results:
- Complete resolution (100% clearance) was achieved in all 39 patients.
- Most lesions (26/39) resolved after the first treatment session.
- Common side effects included pain, erythema, and edema; the procedure was well-tolerated across all age groups.
Conclusions:
- Polidocanol sclerotherapy is highly effective and safe for treating PGs.
- The treatment is cost-effective with no reported recurrences.
- No special post-procedure care is required, simplifying patient management.
More Related Videos
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
52
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
52
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
46
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
46
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
687
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
687
01:29Drugs for Treatment of Ulcerative Colitis in IBD
267
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
267
01:26Peptic Ulcer Disease IV: Management
163
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
163